tranScrip announces appointment of Marcin Mankowski as the new Managing Partner


Dr Marcin Mankowski, Co-founder and Deputy Managing Partner of tranScrip, has been appointed tranScrip’s new Managing Partner.

Marcin has been integral to the success of the business over the last decade and is transitioning to the role at an exciting stage of the company’s growth. Underpinned by a recent significant minority investment from Palatine Private Equity Impact Fund, tranScrip is set to rapidly drive revenues with both organic growth and strategic acquisitions.

Marcin is a highly respected pharmaceutical physician with more than 25 years of big pharma, biotech and service sector managerial experience. He co-founded tranScrip in 2008 as a novel and innovative consultancy model, alongside the current Managing Partner, Dr Flic Gabbay, who is the President Elect of the Faculty of Pharmaceutical Medicine. Together, they successfully built the organisation as a unique, global, leading life sciences consultancy which has generated over £55m of revenues from over 250 pharma and biotech companies as well as grants funding bodies to provide drug development, regulatory and post licensing support.

Marcin Mankowski commented: “I am taking over the leadership of the company with high hopes. We are expanding tranScrip’s geographical reach and further strengthening our expertise in therapy and functional areas to maintain our track record of success for our clients. With our unique team of in-house therapeutic area and operational experts, we are proud to support many research programmes which bring much needed medicines to patients. I would like to thank Flic for her dedication over the last years and I am very pleased that she will continue to be actively involved in tranScrip as member of the Board, the Management Team as well as in our clients’ research programmes.”

I am delighted that Marcin is taking over from me at this critical time in tranScrip’s growth. I am sure that under his leadership tranScrip will maintain its successful track record of supporting early development activities and delivering products to the market for our clients. These will be an emotional few weeks for me as I transition to be President of the Faculty of Pharmaceutical Medicine after being Chair of the Steering Committee which set up the faculty in 1989, and at the same time stepping down from being the Managing Partner of tranScrip to become a more strategic and client facing Partner. I am really excited and look forward to continuing to drive and support life sciences – there is so much to do in this exciting era!

Flic Gabbay

Managing Director, tranScrip